{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:18:10Z","timestamp":1791227890059,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n          <jats:p>Zu den Glucagon-like-peptide-1(GLP-1)-Rezeptoragonisten geh\u00f6ren Albiglutid, Dulaglutid, Exenatid, Liraglutid, Lixisenatid, Orforglipron und Semaglutid. Tirzepatid bindet nicht nur an GLP-1-, sondern auch an glukoseabh\u00e4ngige insulinotrope Peptidrezeptoren (GIP). Retratrutid ist ein dreifacher GLP-1-, GIP- und Glucagonrezeptoragonist. GLP-1-Rezeptoragonisten erh\u00f6hen die Insulin- und unterdr\u00fccken die Glucagonfreisetzung. Sie verlangsamen die Magenentleerung und verhindern so Blutzuckerspitzen. Sie reduzieren den Appetit und die Nahrungsaufnahme. Im Gehirn f\u00fchren GLP-1-Rezeptoragonisten zu einer besseren Blutzuckerkontrolle, und sie scheinen entz\u00fcndungshemmende und neuroprotektive Wirkungen zu haben. Es wurde berichtet, dass GLP-1-Rezeptoragonisten oxidativen Stress und apoptotische Prozesse reduzieren, das Risiko einer Isch\u00e4mie senken und die Neurogenese f\u00f6rdern. GLP-1-Rezeptoragonisten k\u00f6nnen auch die dopaminerge Signaltransduktion im Nucleus accumbens beeinflussen. Somit k\u00f6nnten sie die Wirkung von Kokain, Alkohol und Nikotin ver\u00e4ndern. Vorl\u00e4ufige Untersuchungen weisen auf einen therapeutischen Nutzen von GLP-1-Rezeptoragonisten f\u00fcr Patientinnen und Patienten mit Demenz, Essst\u00f6rungen, psychopharmakologisch induzierter Gewichtszunahme, Depressionen, Angstst\u00f6rungen und Abh\u00e4ngigkeitserkrankungen hin. Typische unerw\u00fcnschte Begleiterscheinungen sind gastrointestinale Nebenwirkungen wie \u00dcbelkeit, Erbrechen, Durchfall, Aufsto\u00dfen und gastro\u00f6sophagealer Reflux. Zu den schwerwiegenderen Nebenwirkungen geh\u00f6ren Pankreatitis, allergische Reaktionen, Nierenfunktionsst\u00f6rungen und m\u00f6glicherweise ein erh\u00f6htes Schilddr\u00fcsenkarzinomrisiko.<\/jats:p>","DOI":"10.1007\/s00115-025-01813-x","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T11:14:18Z","timestamp":1741173258000},"page":"247-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Glucagon-like-peptide-1-Rezeptoragonisten: eine neue pharmakologische Behandlungsoption f\u00fcr psychiatrische Erkrankungen?","Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?"],"prefix":"10.1007","volume":"96","author":[{"given":"Hubertus","family":"Himmerich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"issue":"11","key":"1813_CR1","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1007\/s12325-014-0164-2","volume":"31","author":"Q Du","year":"2014","unstructured":"Du\u00a0Q, Wang\u00a0YJ, Yang\u00a0S et\u00a0al (2014) Liraglutide for the treatment of type\u00a02 diabetes mellitus: a\u00a0meta-analysis of randomized placebo-controlled trials. Adv Ther 31(11):1182\u20131195. https:\/\/doi.org\/10.1007\/s12325-014-0164-2","journal-title":"Adv Ther"},{"key":"1813_CR2","doi-asserted-by":"publisher","first-page":"d7771","DOI":"10.1136\/bmj.d7771","volume":"344","author":"T Vilsb\u00f8ll","year":"2012","unstructured":"Vilsb\u00f8ll\u00a0T, Christensen\u00a0M, Junker\u00a0AE et\u00a0al (2012) Effects of glucagon-like peptide\u20111 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 344:d7771. https:\/\/doi.org\/10.1136\/bmj.d7771","journal-title":"BMJ"},{"issue":"6","key":"1813_CR3","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1053\/j.gastro.2024.01.021","volume":"166","author":"M Arvanitakis","year":"2024","unstructured":"Arvanitakis\u00a0M (2024) No More Needles: Oral semaglutide for weight loss. Gastroenterology 166(6):1190\u20131191. https:\/\/doi.org\/10.1053\/j.gastro.2024.01.021","journal-title":"Gastroenterology"},{"key":"1813_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff\u00a0AM, Aronne\u00a0LJ, Ahmad\u00a0NN et\u00a0al (2022) Tirzepatide once weekly for the treatment of obesity. N\u00a0Engl J Med 387:205\u2013216. https:\/\/doi.org\/10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"issue":"389","key":"1813_CR5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"2023","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff\u00a0AM, Kaplan\u00a0LM, Fr\u00edas\u00a0JP et\u00a0al (2023) Triple-hormone-receptor agonist retatrutide for obesity\u2014A Phase\u00a02 Trial. N\u00a0Engl J Med 2023(389):514\u2013526. https:\/\/doi.org\/10.1056\/NEJMoa2301972","journal-title":"N Engl J Med"},{"issue":"10","key":"1813_CR6","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","volume":"389","author":"S Wharton","year":"2023","unstructured":"Wharton\u00a0S, Blevins\u00a0T, Connery\u00a0L et\u00a0al (2023) Daily Oral GLP\u20111 Receptor Agonist Orforglipron for Adults with Obesity. N\u00a0Engl J Med 389(10):877\u2013888. https:\/\/doi.org\/10.1056\/NEJMoa2302392","journal-title":"N Engl J Med"},{"issue":"19","key":"1813_CR7","doi-asserted-by":"publisher","first-page":"5786","DOI":"10.3390\/jcm13195786","volume":"13","author":"V Prentza","year":"2024","unstructured":"Prentza\u00a0V, Pavlidis\u00a0G, Ikonomidis\u00a0I et\u00a0al (2024) Antidiabetic Treatment and Prevention of Ischemic Stroke: A\u00a0Systematic Review. J\u00a0Clin Med 13(19):5786. https:\/\/doi.org\/10.3390\/jcm13195786","journal-title":"J Clin Med"},{"key":"1813_CR8","doi-asserted-by":"publisher","first-page":"175628642412819","DOI":"10.1177\/17562864241281903","volume":"17","author":"MI Stefanou","year":"2024","unstructured":"Stefanou\u00a0MI, Palaiodimou\u00a0L, Theodorou\u00a0A et\u00a0al (2024) Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP\u20111 RAs or the dual GIP\/GLP\u20111 receptor agonist tirzepatide in overweight or obese adults without diabetes: a\u00a0systematic review and meta-analysis. Ther Adv Neurol Disord 17:17562864241281903. https:\/\/doi.org\/10.1177\/17562864241281903","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"1813_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1515\/mr-2024-0011","volume":"4","author":"S Hoffman","year":"2024","unstructured":"Hoffman\u00a0S, Adeli\u00a0K (2024) Glucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism. Med Rev 4(4):301\u2013311. https:\/\/doi.org\/10.1515\/mr-2024-0011","journal-title":"Med Rev"},{"issue":"4","key":"1813_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1515\/mr-2024-0011","volume":"4","author":"RJ MacIsaac","year":"2024","unstructured":"MacIsaac\u00a0RJ, Trevella\u00a0P, Ekinci\u00a0EI (2024) Glucagon-like peptide\u20111 receptor agonists and kidney outcomes. J\u00a0Diabetes 4(4):301\u2013311. https:\/\/doi.org\/10.1515\/mr-2024-0011","journal-title":"J Diabetes"},{"key":"1813_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/ANA.0000000000000985","author":"HLR Guevara","year":"2024","unstructured":"Guevara\u00a0HLR, Beam\u00a0WBB, Pasternak\u00a0JJ (2024) To the Brain and Beyond: Neurological Implications of Glucagon-Like Peptide\u20111 Receptor Agonists. J\u00a0Neurosurg Anesthesiol\u00a036(4):278-282. https:\/\/doi.org\/10.1097\/ANA.0000000000000985","journal-title":"J Neurosurg Anesthesiol"},{"issue":"3","key":"1813_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/JCP.0000000000001869","volume":"44","author":"H Himmerich","year":"2024","unstructured":"Himmerich\u00a0H, McElroy\u00a0SL (2024) Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry. J\u00a0Clin Psychopharmacol 44(3):207\u2013210. https:\/\/doi.org\/10.1097\/JCP.0000000000001869","journal-title":"J Clin Psychopharmacol"},{"key":"1813_CR13","doi-asserted-by":"publisher","first-page":"123001","DOI":"10.1016\/j.lfs.2024.123001","volume":"355","author":"J Tran","year":"2024","unstructured":"Tran\u00a0J, Parekh\u00a0S, Rockcole\u00a0J et\u00a0al (2024) Repurposing antidiabetic drugs for Alzheimer\u2019s disease: A\u00a0review of preclinical and clinical evidence and overcoming challenges. Life Sci 355:123001. https:\/\/doi.org\/10.1016\/j.lfs.2024.123001","journal-title":"Life Sci"},{"key":"1813_CR14","doi-asserted-by":"publisher","first-page":"107312","DOI":"10.1016\/j.phrs.2024.107312","volume":"207","author":"N Bruns Vi","year":"2024","unstructured":"Bruns Vi\u00a0N, Tressler\u00a0EH, Vendruscolo\u00a0LF et\u00a0al (2024) IUPHAR review\u2014Glucagon-like peptide\u20111 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target. Pharmacol Res 207:107312. https:\/\/doi.org\/10.1016\/j.phrs.2024.107312","journal-title":"Pharmacol Res"},{"key":"1813_CR15","doi-asserted-by":"publisher","first-page":"113537","DOI":"10.1016\/j.intimp.2024.113537","volume":"143","author":"N Siddeeque","year":"2024","unstructured":"Siddeeque\u00a0N, Hussein\u00a0MH, Abdelmaksoud\u00a0A et\u00a0al (2024) Neuroprotective effects of GLP\u20111 receptor agonists in neurodegenerative Disorders: A\u00a0Large-Scale Propensity-Matched cohort study. Int Immunopharmacol 143:113537. https:\/\/doi.org\/10.1016\/j.intimp.2024.113537","journal-title":"Int Immunopharmacol"},{"key":"1813_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13063-019-3259-x","volume":"20","author":"GD Femminella","year":"2019","unstructured":"Femminella\u00a0GD, Frangou\u00a0E, Love\u00a0SB et\u00a0al (2019) Evaluating the effects of the novel GLP\u20111 analogue liraglutide in Alzheimer\u2019s disease: study protocol for a\u00a0randomised controlled trial (ELAD study). Trials 20:191. https:\/\/doi.org\/10.1186\/s13063-019-3259-x","journal-title":"Trials"},{"key":"1813_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","volume":"17","author":"JL Cummings","year":"2025","unstructured":"Cummings\u00a0JL, Atri\u00a0A, Feldman\u00a0HH et\u00a0al (2025) evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase\u00a03\u00a0studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer\u2019s disease. Alzheimers Res Ther 17:14. https:\/\/doi.org\/10.1186\/s13195-024-01666-7","journal-title":"Alzheimers Res Ther"},{"key":"1813_CR18","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.orcp.2015.03.005","volume":"9","author":"SA Robert","year":"2015","unstructured":"Robert\u00a0SA, Rohana\u00a0AG, Shah\u00a0SA et\u00a0al (2015) Improvement in binge eating in non-diabetic obese individuals after 3\u00a0months of treatment with liraglutide\u2014a pilot study. Obes Res Clin Pract 9:301\u2013304. https:\/\/doi.org\/10.1016\/j.orcp.2015.03.005","journal-title":"Obes Res Clin Pract"},{"key":"1813_CR19","doi-asserted-by":"publisher","first-page":"100080","DOI":"10.1016\/j.obpill.2023.100080","volume":"7","author":"J Richards","year":"2023","unstructured":"Richards\u00a0J, Bang\u00a0N, Ratliff\u00a0EL et\u00a0al (2023) Successful treatment of binge eating disorder with the GLP\u20111 agonist semaglutide: A\u00a0retrospective cohort study. Obes Pillars 7:100080. https:\/\/doi.org\/10.1016\/j.obpill.2023.100080","journal-title":"Obes Pillars"},{"issue":"8","key":"1813_CR20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/15622975.2023.2179663","volume":"24","author":"H Himmerich","year":"2023","unstructured":"Himmerich\u00a0H, Lewis\u00a0YD, Conti\u00a0C et\u00a0al (2023) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders. World J Biol Psychiatry 24(8):643\u2013706. https:\/\/doi.org\/10.1080\/15622975.2023.2179663","journal-title":"World J Biol Psychiatry"},{"key":"1813_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/osp4.619","volume":"9","author":"KC Allison","year":"2022","unstructured":"Allison\u00a0KC, Chao\u00a0AM, Bruzas\u00a0MB et\u00a0al (2022) A pilot randomized controlled trial of liraglutide 3.0\u202fmg for binge eating disorder. Obes Sci Pract 9:127\u2013136. https:\/\/doi.org\/10.1002\/osp4.619","journal-title":"Obes Sci Pract"},{"key":"1813_CR22","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","volume":"74","author":"JR Larsen","year":"2017","unstructured":"Larsen\u00a0JR, Vedtofte\u00a0L, Jakobsen\u00a0MSL et\u00a0al (2017) Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: A\u00a0randomized clinical trial. JAMA Psychiatry 74:719\u2013728. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.1220","journal-title":"JAMA Psychiatry"},{"key":"1813_CR23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3892\/etm.2023.12054","volume":"26","author":"O Vasiliu","year":"2023","unstructured":"Vasiliu\u00a0O (2023) Therapeutic management of atypical antipsychotic-related metabolic dysfunctions using GLP\u20111 receptor agonists: A\u00a0systematic review. Exp Ther Med 26:355. https:\/\/doi.org\/10.3892\/etm.2023.12054","journal-title":"Exp Ther Med"},{"issue":"8","key":"1813_CR24","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1017\/S0033291723003586","volume":"54","author":"B Applewhite","year":"2024","unstructured":"Applewhite\u00a0B, Penninx\u00a0BWJH, Young\u00a0AH et\u00a0al (2024) The effect of a\u00a0low-calorie diet on depressive symptoms in individuals with overweight or obesity: a\u00a0systematic review and meta-analysis of interventional studies. Psychol Med 54(8):1671\u20131683. https:\/\/doi.org\/10.1017\/S0033291723003586","journal-title":"Psychol Med"},{"issue":"1","key":"1813_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jagp.2023.08.010","volume":"32","author":"X Chen","year":"2024","unstructured":"Chen\u00a0X, Zhao\u00a0P, Wang\u00a0W et\u00a0al (2024) The Antidepressant Effects of GLP\u20111 Receptor Agonists: A\u00a0Systematic Review and Meta-Analysis. Am J Geriatr Psychiatry 32(1):117\u2013127. https:\/\/doi.org\/10.1016\/j.jagp.2023.08.010","journal-title":"Am J Geriatr Psychiatry"},{"key":"1813_CR26","unstructured":"Miller A, Joyce B, Bartelt K, Deckert J Most GLP\u20111 Medications Correlated with a\u00a0Lower Likelihood of Anxiety and Depression Diagnoses. https:\/\/www.epicresearch.org\/articles\/most-glp-1-medications-correlated-with-a-lower-likelihood-of-anxiety-and-depression-diagnoses. Zugegriffen: 27. Okt. 2024"},{"issue":"5","key":"1813_CR27","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/bcpt.13776","volume":"131","author":"IK Wium-Andersen","year":"2022","unstructured":"Wium-Andersen\u00a0IK, Wium-Andersen\u00a0MK, Fink-Jensen\u00a0A et\u00a0al (2022) Use of GLP\u20111 receptor agonists and subsequent risk of alcohol-related events. A\u00a0nationwide register-based cohort and self-controlled case series study. Basic Clin Pharmacol Toxicol 131(5):372\u2013379. https:\/\/doi.org\/10.1111\/bcpt.13776","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1813_CR28","doi-asserted-by":"publisher","first-page":"e159863","DOI":"10.1172\/jci.insight.159863","volume":"7","author":"MK Klausen","year":"2022","unstructured":"Klausen\u00a0MK, Jensen\u00a0ME, M\u00f8ller\u00a0M et\u00a0al (2022) Exenatide once weekly for alcohol use disorder investigated in a\u00a0randomized, placebo-controlled clinical trial. JCI Insight 7:e159863. https:\/\/doi.org\/10.1172\/jci.insight.159863","journal-title":"JCI Insight"},{"issue":"1","key":"1813_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/00325481.2021.2002616","volume":"134","author":"S Wharton","year":"2022","unstructured":"Wharton\u00a0S, Davies\u00a0M, Dicker\u00a0D et\u00a0al (2022) Managing the gastrointestinal side effects of GLP\u20111 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med 134(1):14\u201319. https:\/\/doi.org\/10.1080\/00325481.2021.2002616","journal-title":"Postgrad Med"},{"key":"1813_CR30","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/dom.15382","volume":"26","author":"GA Silverii","year":"2024","unstructured":"Silverii\u00a0GA, Monami\u00a0M, Gallo\u00a0M et\u00a0al (2024) Glucagon-like peptide\u20111 receptor agonists and risk of thyroid cancer: A\u00a0systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 26:891\u2013900. https:\/\/doi.org\/10.1111\/dom.15382","journal-title":"Diabetes Obes Metab"},{"key":"1813_CR31","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3390\/ph16070994","volume":"16","author":"S Chiappini","year":"2023","unstructured":"Chiappini\u00a0S, Vickers-Smith\u00a0R, Harris\u00a0D et\u00a0al (2023) Is there a\u00a0risk for semaglutide misuse? Focus on the Food and Drug Administration\u2019s FDA Adverse Events Reporting System (FAERS) pharmacovigilance dataset. Pharmaceuticals 16:994. https:\/\/doi.org\/10.3390\/ph16070994","journal-title":"Pharmaceuticals"},{"key":"1813_CR32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/JCP.0000000000001820","volume":"44","author":"AI Guerdjikova","year":"2024","unstructured":"Guerdjikova\u00a0AI, Ward\u00a0A, Ontiveros\u00a0M, McElroy\u00a0SL (2024) Semaglutide Misuse in Atypical Anorexia Nervosa\u2014A Case Report. J\u00a0Clin Psychopharmacol 44:179\u2013180. https:\/\/doi.org\/10.1097\/JCP.0000000000001820","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"1813_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","volume":"23","author":"RS McIntyre","year":"2024","unstructured":"McIntyre\u00a0RS, Mansur\u00a0RB, Rosenblat\u00a0JD et\u00a0al (2024) The association between glucagon-like peptide\u20111 receptor agonists (GLP\u20111 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf 23(1):47\u201355. https:\/\/doi.org\/10.1080\/14740338.2023.2295397","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"1813_CR34","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1111\/dom.15538","volume":"26","author":"GA Silverii","year":"2024","unstructured":"Silverii\u00a0GA, Marinelli\u00a0C, Mannucci\u00a0E et\u00a0al (2024) Glucagon-like peptide\u20111 receptor agonists and mental health: A\u00a0meta-analysis of randomized controlled trials. Diabetes Obes Metab 26(6):2505\u20132508. https:\/\/doi.org\/10.1111\/dom.15538","journal-title":"Diabetes Obes Metab"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-025-01813-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-025-01813-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-025-01813-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T08:21:10Z","timestamp":1746606070000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-025-01813-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1813"],"URL":"https:\/\/doi.org\/10.1007\/s00115-025-01813-x","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"31 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"H.\u00a0Himmerich ist Principal Investigator (PI) einer vom National Institute for Health and Care Research (NIHR) finanzierten Machbarkeitsstudie, in der Olanzapin bei jungen PatientInnen mit Anorexia nervosa getestet wird, und PI einer von COMPASS Pathways finanzierten und gesponserten Proof-of-Concept-Studie, in der Psilocybin bei Anorexia nervosa getestet wird. Er erh\u00e4lt einen Teil seines Gehalts vom NIHR Biomedical Research Centre (BRC) des Maudsley NHS Foundation Trust und des des King\u2019s College London.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}